Mode of Action and Clinical Applications of Dobutamine

Receptor Interactions and Hemodynamic Effects

Dobutamine acts directly on multiple adrenergic receptors in the cardiovascular system, with strong stimulation of β1-adrenergic receptors in the myocardium and mild stimulation of α1-adrenergic receptors, contributing to its selective inotropic effect 1
Dobutamine primarily increases cardiac output by augmenting stroke volume rather than heart rate 1
At low doses, dobutamine induces mild arterial vasodilation, which further enhances stroke volume by reducing afterload 1
At higher doses, dobutamine may cause vasoconstriction due to increased α1-receptor stimulation 1, 2
Heart rate increases in a dose-dependent manner but generally to a lesser extent than with other catecholamines 1
In patients with atrial fibrillation, dobutamine may increase heart rate to undesirable levels due to facilitation of atrioventricular conduction 1

Dobutamine is indicated for short-term management of heart failure, particularly in patients with reduced cardiac output 2
Typical dosing range: 2-20 μg/kg/min, with titration based on individual patient response 2
Prolonged infusion (>24-48 hours) may lead to tolerance and partial loss of hemodynamic effects 1
Increased incidence of arrhythmias (both atrial and ventricular), which is dose-related 1, 2
Potential for myocardial ischemia in patients with coronary artery disease 1, 3
May increase myocardial oxygen demand 3
In patients with hibernating myocardium, dobutamine may increase contractility short-term at the expense of myocyte necrosis 1

The inotropic effect of dobutamine is additive to that of phosphodiesterase inhibitors, with their combination producing greater inotropic effect than either drug alone 1